MicOryx

MicOryx is an investigational therapeutic cancer vaccine developed by ORYX in collaboration with researchers at the University of Heidelberg. It is specifically designed for the treatment and prevention of cancers characterized by DNA mismatch repair (MMR) deficiency, such as colorectal cancer associated with Lynch syndrome. The vaccine is a trivalent formulation consisting of three synthetic frameshift peptide (FSP) neoantigens derived from recurrent mutations in the *AIM2*, *HT001* (also known as *ASTE1*), and *TAF1B* genes. These mutations are highly prevalent in MMR-deficient tumors due to microsatellite instability. Formulated with the adjuvant Montanide ISA-51 VG to enhance immunogenicity, MicOryx aims to stimulate the patient's immune system to mount both cellular (T-cell) and humoral (antibody) responses against cancer cells expressing these neoantigens. Clinical data from Phase I/IIa trials have demonstrated that the vaccine is well-tolerated and capable of inducing specific immune responses in patients with a history of dMMR colorectal cancer.

Brand names

MicOryx

Other names

FSP neoantigen vaccineFrameshift peptide neoantigen vaccine